Signal from the log
Shennon Biotechnologies
12 M$ · Undisclosed · United States · Biotech
Shennon Biotechnologies conçoit des T-cell engagers, des anticorps qui accrochent un lymphocyte T à une cellule tumorale. Née en 2021 à San Francisco, elle crible à très haut débit pour trouver des cibles propres à la tumeur. Ses trois programmes, poumon à petites cellules, ovaire et foie, sont précliniques.
Verified
Announced on , logged by the watch of 14 September 2026.
- Operation
- Funding round
- Announced amount
- 12 M$
- Stage
- Undisclosed
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
With Future Ventures , NextGen Venture Partners , Samos Investments , Atypical Ventures , Saras Capital
Provenance
Source businesswire,fortune,pulse2
Logged on 14 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.